Skip to main content
DeutschDE
European Commission logo print header

TOWARDS CONTROL OF EMERGING AFRICAN HORSESICKNESS DISEASE

Ziel



The objective are:

- to develop a new type of vaccine for African horsesickness (AHS) disease;
- to develop a diagnostic reagent to differentiate between vaccinated and infected animals.

Specific objectives are:

- To express 2 or 4 capsid proteins of AHSV-4 using available cDNA clones and baculovirus vectors and synthesize empty virus-like particles (VLPs).
- To evaluate the immunological properties of VLPs in model animals (e.g. mice).
- To characterize humoral and cell-mediated immunity elicited by VLPs.
- To evaluate protective efficiency of VLPs in natural vertebrate hosts (e.g. horse).
- To synthesize a non-structural viral-coded AHSV NS1 protein (ie a non-capsid protein) using a baculovirus vector and to caharacterise the expressed protein immunogically and biochemically.
- To purify the expressed protein and use the protein to distinguish between vaccinated and naturally-infected animals.
- To generate cDNA clones of other AHSV serotypes that are needed to synthesize VLPs for other serotypes.

Wissenschaftliches Gebiet

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

Data not available

Finanzierungsplan

CSC - Cost-sharing contracts

Koordinator

University of Oxford
EU-Beitrag
Keine Daten
Adresse
South Parks Road
OX1 3QU Oxford
Vereinigtes Königreich

Auf der Karte ansehen
Gesamtkosten
Keine Daten

Beteiligte (1)

Diese Seite teilen

Herunterladen

Letzte Aktualisierung: 2 November 1995

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/AIR21790/de

European Union, 2024